Atherosclerosis Market to Rise by 2032 | Regeneron, Sanofi, Immunitor, Novartis, MedImmune, Cerenis Therapeutics, AFFiRiS, VBL Therapeutics, Abcentra, Millennium Pharmaceuticals, Daiichi Sankyo, Band Therapeutic, Innomedica, Chugai Pharmaceutical, Repair

DelveInsight's "Atherosclerosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Atherosclerosis, historical and forecasted epidemiology as well as the Atherosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Atherosclerosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atherosclerosis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Atherosclerosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Atherosclerosis market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/atherosclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the atherosclerosis market report:

The atherosclerosis market is projected to experience a steady Compound Annual Growth Rate (CAGR) during the forecast period from 2024 to 2034. This growth is primarily fueled by advancements in diagnostic techniques, heightened awareness of the condition, and an increasing number of reported cases.
The rise in atherosclerosis cases can be attributed to several factors, including high blood pressure, diabetes, poor nutrition, stress, sleep apnea, and exposure to chemicals from smoking and tobacco.
According to secondary analysis data, coronary artery atherosclerosis is the leading cause of death among both men and women in the United States.
The current atherosclerosis market is highly competitive, featuring established key players such as Novartis, Esperion Therapeutics, and Agepha Pharma, among others.
Looking ahead, several companies, including Amgen, New Amsterdam Pharma, and Silence Therapeutics, are advancing their products in the mid to late stages of development. With the anticipated approval of these therapies during the forecast period, the overall therapeutic market for atherosclerosis is expected to witness significant growth.
In June 2023, the U.S. FDA approved LODOCO (colchicine, 0.5 mg tablets) as the first anti-inflammatory atheroprotective cardiovascular treatment shown to reduce the risk of cardiovascular death in adults with established atherosclerotic disease.
In 2021, the FDA also approved Novartis' LEQVIO (inclisiran), which is the first and only small interfering RNA (siRNA) therapy designed to lower low-density lipoprotein cholesterol (LDL-C), commonly referred to as "bad cholesterol." This treatment involves two doses per year, following an initial dose and one at three months.
Additionally, in 2020, the FDA approved NEXLIZET and NEXLETOL for adults with established atherosclerotic cardiovascular disease who need further lowering of LDL-C.

Atherosclerosis Overview

Atherosclerosis is a condition characterized by the buildup of fatty deposits (plaque) in the walls of arteries, leading to narrowed or blocked arteries. This can reduce blood flow and result in serious cardiovascular problems, such as heart attack and stroke. Atherosclerosis often develops slowly over decades and may not show symptoms until significant blockage occurs.

Causes
The exact cause of atherosclerosis is complex and multifactorial, involving various risk factors, including:

High Cholesterol: Elevated levels of low-density lipoprotein (LDL) cholesterol can contribute to plaque buildup.
Hypertension: High blood pressure can damage arterial walls, making them more susceptible to plaque accumulation.
Smoking: Tobacco use damages blood vessels and accelerates atherosclerosis.
Diabetes: High blood sugar levels can lead to increased plaque formation.
Obesity: Excess body weight is linked to high cholesterol, high blood pressure, and diabetes.
Sedentary Lifestyle: Lack of physical activity contributes to many risk factors associated with atherosclerosis.
Unhealthy Diet: Diets high in saturated fats, trans fats, and cholesterol can increase plaque buildup.
Genetics: A family history of heart disease can increase risk.
Signs and Symptoms
Atherosclerosis may not cause noticeable symptoms until a significant blockage occurs. Symptoms can vary based on the arteries affected:

Coronary Arteries (heart):

Chest pain (angina)
Shortness of breath
Heart attack (sudden severe chest pain, sweating, nausea)
Carotid Arteries (brain):

Sudden numbness or weakness in the face or limbs
Difficulty speaking
Stroke (sudden severe headache, confusion, vision problems)
Peripheral Arteries (limbs):

Pain or cramping in the legs during physical activity (claudication)
Weak or absent pulses in the legs or feet
Diagnosis
Diagnosis of atherosclerosis typically involves several steps:

Medical History and Physical Exam: Assessment of risk factors, symptoms, and family history.

Blood Tests: To check cholesterol levels, blood sugar, and other markers of heart health.

Imaging Tests:

Ultrasound: To assess blood flow and identify plaque buildup.
CT Angiography: Non-invasive imaging to visualize arteries.
Magnetic Resonance Angiography (MRA): Uses magnetic fields to visualize blood vessels.
Stress Tests: To evaluate how the heart functions under stress, often using exercise or medication to stimulate the heart.

Angiography: Invasive procedure using dye and X-rays to visualize blood vessels directly.

Treatment Options
Treatment for atherosclerosis focuses on reducing risk factors and managing symptoms:

Lifestyle Modifications:

Diet: Adoption of a heart-healthy diet low in saturated fats, trans fats, and cholesterol.
Exercise: Regular physical activity to improve cardiovascular health.
Weight Management: Achieving and maintaining a healthy weight.
Medications:

Statins: To lower cholesterol levels and reduce plaque buildup.
Antiplatelet Agents: Such as aspirin to prevent blood clots.
Antihypertensives: To manage high blood pressure.
Diabetes Medications: To control blood sugar levels.
Medical Procedures:

Angioplasty and Stenting: A procedure to open blocked arteries using a balloon and placing a stent to keep it open.
Bypass Surgery: Creating a new pathway for blood flow around blocked arteries.
Regular Monitoring: Ongoing evaluation of cardiovascular health and management of risk factors is essential.

Prognosis
The prognosis for individuals with atherosclerosis depends on the severity of the condition and the effectiveness of management strategies. Early detection and lifestyle changes can significantly reduce the risk of serious complications, such as heart attack and stroke. Regular follow-up with healthcare providers is crucial for monitoring and maintaining cardiovascular health.

Learn more about Atherosclerosis, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/atherosclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atherosclerosis Market

The Atherosclerosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Atherosclerosis market trends by analyzing the impact of current Atherosclerosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Atherosclerosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Atherosclerosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Atherosclerosis market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/atherosclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atherosclerosis Epidemiology

The analysis of atherosclerosis identified it as a chronic inflammatory disease of the arteries, which contributes to approximately 50% of all deaths in Western societies. Each year, around 610,000 people in the United States die from heart disease. Notably, about 75% of acute myocardial infarctions in the U.S. are linked to plaque rupture.

The analysis also found that atherosclerosis is more prevalent in men than in women, likely due to the protective effects of female sex hormones, which decline after menopause. In high-income countries, the average age-specific prevalence of peripheral artery disease (PAD) ranges from about 5% among individuals aged 40 to 49 years to 13% among those aged 70 to 79 years.

The epidemiology of atherosclerosis is anticipated to evolve during the forecast period from 2024 to 2034.

Explore more about Atherosclerosis Epidemiology at: https://www.delveinsight.com/report-store/atherosclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atherosclerosis Marketed Drugs

LEQVIO (inclisiran): Novartis
NEXLETOL (bempedoic acid): Esperion Therapeutics
LODOCO (colchicine, 0.5 mg tablets): Agepha Pharma

Atherosclerosis Emerging Drugs

Olpasiran: Amgen
Obicetrapib: NewAmsterdam Pharma
Zerlasiran: Silence Therapeutics

Atherosclerosis Pipeline Development Activities

The Atherosclerosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Atherosclerosis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Atherosclerosis pipeline development activities at: https://www.delveinsight.com/sample-request/atherosclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atherosclerosis Therapeutics Assessment

Major pharma companies such as Regeneron, Sanofi, Immunitor, Novartis, MedImmune, Cerenis Therapeutics, AFFiRiS, VBL Therapeutics, Abcentra, Millennium Pharmaceuticals, Daiichi Sankyo, Band Therapeutic, Innomedica, Chugai Pharmaceutical, Repair Biotechnologies, Northstar medical radioisotopes, Entos therapeutics, Caladrius Biosciences, Novo Nordisk, Esperion Therapeutics, Immusoft Corp, Kaleido Biosciences, Takeda Pharmaceutical, MetrioPharm, and others are working proactively in the Atherosclerosis Therapeutics market to develop novel therapies which will drive the Atherosclerosis treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/atherosclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atherosclerosis Report Key Insights

1. Atherosclerosis Patient Population
2. Atherosclerosis Market Size and Trends
3. Key Cross Competition in the Atherosclerosis Market
4. Atherosclerosis Market Dynamics (Key Drivers and Barriers)
5. Atherosclerosis Market Opportunities
6. Atherosclerosis Therapeutic Approaches
7. Atherosclerosis Pipeline Analysis
8. Atherosclerosis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Atherosclerosis Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Atherosclerosis Competitive Intelligence Analysis
4. Atherosclerosis Market Overview at a Glance
5. Atherosclerosis Disease Background and Overview
6. Atherosclerosis Patient Journey
7. Atherosclerosis Epidemiology and Patient Population
8. Atherosclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Atherosclerosis Unmet Needs
10. Key Endpoints of Atherosclerosis Treatment
11. Atherosclerosis Marketed Products
12. Atherosclerosis Emerging Therapies
13. Atherosclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Atherosclerosis Market Outlook (7 major markets)
16. Atherosclerosis Access and Reimbursement Overview
17. KOL Views on the Atherosclerosis Market
18. Atherosclerosis Market Drivers
19. Atherosclerosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Atherosclerosis Market report here: https://www.delveinsight.com/report-store/atherosclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.